Acquisition of Activaero

Posted Posted in Fund news, News, Portfolio News

Vectura Group plc (LSE: VEC; “Vectura” or the “Company”) announces the acquisition of Activaero GmbH (“Activaero”) for a total consideration of €130 million (£108 million) to be funded through a combination of existing cash and equity. Activaero is a private German pharmaceutical company focused on the development of products for the treatment of respiratory diseases. Its proprietary smart Read the full article…

Altoida Logo

Altoida Raises $6.3m Series A to predict Alzheimer’s disease risk using AI, machine learning and augmented reality

Posted Posted in Fund news, News, Portfolio News

Altoida Inc. today announced a $6.3 million round of venture capital financing to bring its FDA-cleared and CE Mark-approved medical device and brain health data platform to patients, physicians and researchers around the globe. Led by a team of esteemed neuroscientists, physicians and computer scientists, Altoida uses digital biomarkers to drive better clinical outcomes for Read the full article…

Amal Therapeutics Logo

AMAL Therapeutics enters clinical collaboration with Boehringer Ingelheim to evaluate ATP128 in combination with BI754091

Posted Posted in News, Portfolio News

AMAL Therapeutics (AMAL), a Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has entered into a collaborative agreement with Boehringer Ingelheim. AMAL will conduct an international Phase Ib clinical study, referred to as KISIMA-01, to evaluate the combination of its lead candidate, ATP128, with Boehringer Ingelheim’s anti-PD1 compound, BI754091, in Microsatellite Read the full article…

Amal Therapeutics Logo

AMAL Therapeutics finalises €29m (CHF 33.2m) Series B round

Posted Posted in Fund news, News, Portfolio News

AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the second closing of its Series B financing round. The second and final tranche of €21.2 million (CHF 24.2 million) brings the total round to just over €29 million (CHF 33.2 million). The Company will use the Read the full article…

Amal Therapeutics Logo

Amal Therapeutics raises CHF 3 million

Posted Posted in Fund news, News, Portfolio News

Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round which will help progress Amal’s cancer vaccines. Amal Therapeutics is a Swiss biotech company developing and progressing therapeutic cancer vaccines. The company Read the full article…

CeQur Logo

Analysis demonstrates CeQur PAQ insulin delivery device is highly cost effective for people with Type 2 Diabetes not in glycemic control

Posted Posted in Fund news, News, Portfolio News

CeQur® today announced that the Journal of Health Economics and Outcomes Research (JHEOR) published online an analysis evaluating the cost effectiveness of the company’s PAQ® Insulin Delivery Device. The analysis suggests that the simple three-day, wearable PAQ basal-bolus insulin delivery device is more cost-effective than multiple daily insulin injections (MDI) and results in a lifetime cost savings of more Read the full article…

Araris Logo

Araris appoints Chief Development Officer

Posted Posted in Portfolio News

Araris Biotech AG, a company pioneering antibody-drug conjugate (ADC)-linker technology, announced today that it has recruited Dr. Bernd Schlereth as Chief Development Officer (CDO). He brings with him more than 20 years of experience in pharmaceutical drug development. Between 2019 and 2021 Dr. Bernd Schlereth worked as Vice President Oncology Research at Molecular Partners AG. Read the full article…

Araris Logo

Araris Biotech AG closes seed financing round of CHF 2.5m

Posted Posted in Fund news, News, Portfolio News

Zurich, Switzerland – August 20, 2019: Araris Biotech AG announced today the closing of an oversubscribed seed financing round of CHF 2.5 million with participation of Swiss investors Redalpine, Schroder Adveq and VI Partners. The proceeds will be used to develop a pipeline of proprietary antibody-drug conjugates (ADCs). Araris’ co-founder and Chief Executive Officer, Dr. Read the full article…

Sumup Logo

BancoEstado and SumUp to launch mobile card acceptance in Chile

Posted Posted in News, Portfolio News

SumUp, the leading financial technology provider, and BancoEstado de Chile, the largest national bank of Chile, today announce the launch of a joint venture offering mobile card acceptance to small businesses. BancoEstado ran a comprehensive global selection process from which SumUp emerged as the ideal partner to serve small merchants in Chile. Through the newly Read the full article…

Amal Therapeutics Logo

Boehringer Ingelheim acquires AMAL Therapeutics

Posted Posted in Fund news, Portfolio News

Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this Read the full article…

Cell Medica Logo

Cell Medica Acquires Delenex Therapeutics

Posted Posted in Fund news, News, Portfolio News

Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and viral infections, announced today the acquisition of Delenex Therapeutics AG, a privately held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. The acquisition will enable Cell Medica to accelerate the development of gene-modified immune Read the full article…

Cell Medica Logo

Cell Medica awarded US$ 8.7m CPRIT grant to accelerate CMD-502 off-the-shelf CAR-NKT cell therapy into clinical development

Posted Posted in News, Portfolio News

Cell Medica announced today that it has been awarded an $8.7 million research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The grant will support preclinical and clinical development of the company’s off-the-shelf chimeric antigen receptor-natural killer T cell (CAR-NKT) therapies to treat hematological and solid tumors. The CPRIT grant will support Read the full article…

Cell Medica Logo

Cell Medica collaborators, Baylor College of Medicine and Texas Children’s Hospital, present positive early patient data from CAR-NKT neuroblastoma trial

Posted Posted in News, Portfolio News

Cell Medica, a leader in next-generation cellular immunotherapies for the treatment of cancer, today announced that its collaborators from Baylor College of Medicine and Texas Children’s Hospital presented the latest positive progress in the GINAKIT2 trial for children with R/R high risk neuroblastoma at the 22nd Annual Meeting of the American Society of Gene & Cell Read the full article…

Cell Medica Logo

Cell Medica collaborators, Baylor College of Medicine and Texas Children’s Hospital, present preclinical data for an off-the-shelf CAR-NKT therapy platform

Posted Posted in News, Portfolio News

Cell Medica, a leader in next-generation cellular immunotherapies for the treatment of cancer, today announced that collaborators from Baylor College of Medicine and Texas Children’s Hospital presented the latest preclinical data generated as part of the development program for CMD-502, an off-the-shelf CAR-NKT therapy candidate for R/R CD19 expressing B-cell malignancies, at the 22nd Annual Meeting Read the full article…

CeQur Logo

CeQur appoints Bradley Paddock Chief Executive Officer

Posted Posted in News, Portfolio News

CeQur® announced that the company has appointed Bradley Paddock as chief executive officer, effective today. Paddock brings a track record of commercial medtech successes, notably leading sales up to $600 million during his eight-year tenure at Kyphon, Inc. Paddock also managed successful commercial operations for multiple industry-leading companies, including Stryker, Bausch + Lomb, Inc., and Read the full article…

Kuros Biosciences Logo

Cytos Biotechnology and Kuros Biosurgery to combine to create Kuros Biosciences

Posted Posted in Fund news, News, Portfolio News

Cytos Biotechnology Ltd. (SIX:CYTN) (“Cytos”) and Kuros Biosurgery Holding AG (“Kuros”), today announced their intention to combine their businesses by way of an exchange of Kuros shares for new Cytos shares, subject to shareholder approval and other customary conditions. Cytos is listed on the main segment of the Swiss stock exchange (SIX Swiss Exchange) while Read the full article…

CeQur Logo

Data from multiple studies demonstrate CeQur PAQ basal-bolus insulin delivery device is a successful alternative to multiple daily insulin injections

Posted Posted in News, Portfolio News

CeQur announced that the Journal of Diabetes Science and Technology (JDST) has published a paper summarizing data from multiple studies evaluating whether the company’s PAQ basal-bolus insulin delivery device overcomes barriers to insulin delivery and meets the needs of people with type 2 diabetes and their healthcare providers. The data demonstrate that the simple three-day, Read the full article…

Euippo Logo

Equippo closes financing round and expands to Belgium

Posted Posted in Fund news, News, Portfolio News

Equippo, an online marketplace for construction equipment, has acquired a Berlin-based startup and simultaneously expanded its services with a permanent auction yard in Belgium. These strategic moves come after Equippo closed a new financing round from existing investors. Equippo’s online platform, allows customers to purchase used heavy equipment from the US and Europe selling as high as 500,000 US dollars. Read the full article…

Ledgy Logo

Equity management platform Ledgy secures €1m for expansion in Europe

Posted Posted in Fund news, News, Portfolio News

Ledgy AG, Zurich (Switzerland), provider of equity software for private companies, has collected 1 million euros in a successful seed round. The company secured funding from a strong alliance of European investors: In addition to btov Partners (St. Gallen, Switzerland), Creathor Ventures (Bad Homburg, Germany) and VI Partners (Zug, Switzerland) are involved. Daniel Gutenberg and Read the full article…

Genkyotex Logo

Final data analysis shows that GKT831 demonstrated statistically significant improvements in GGT and ALP over full treatment period

Posted Posted in News, Portfolio News

Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) announced today the final results of its Phase 2 trial of GKT831 in primary biliary cholangitis (PBC). These data include pre-determined secondary efficacy analyses that were not previously available, as well as full safety data. The efficacy results demonstrate that GKT831 at the 400mg twice a day (BID) Read the full article…

GAMAYA closes CHF 3.2 Million Series A to boost the deployment of their advanced crop analytics services

Posted Posted in Fund news, News, Portfolio News

Gamaya, provider of the world’s most advanced solution for large-scale diagnostics of farmland using hyperspectral imaging and artificial intelligence, announced it has raised 3.2 Million in a series A financing round. Investors include Sandoz Foundation, Peter Brabeck-Letmathe (Chairman of Nestle), Seed4Equity (social-impact investment fund), as well as well-established Swiss venture capital firm VI Partners. All Read the full article…

Genkyotex Logo

Gemkyotex announces completion of 24-week treatment of its phase 2 trial with GKT831 in primary biliary cholangitis

Posted Posted in News, Portfolio News

Genkyotex (Euronext Paris & Brussels: FR0011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that the last patient has completed on March 8, 2019 the full 24-week treatment in its Phase 2 trial of GKT831 in patients with Primary Biliary Cholangitis (PBC). Positive interim efficacy results after 6 weeks of Read the full article…

Genkyotex Logo

Genkyotex announces complete enrollment in interim analysis cohort of phase 2 trial of GKT831 in primary biliary cholangitis

Posted Posted in Fund news, News, Portfolio News

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that 90 patients have been randomized in its Phase 2 trial of GKT831 for the treatment of Primary Biliary Cholangitis (PBC). This represents the target number of patients required to conduct the pre-planned interim analysis. The Read the full article…

Genkyotex Logo

Genkyotex announces positive outcome from independent SMB’s first pre-planed review of GKT831’s Phase 2 trial in primary biliary cholangitis

Posted Posted in News, Portfolio News

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced that the independent Safety Monitoring Board (SMB) for its Phase 2 trial of GKT831 for the treatment of Primary Biliary Cholangitis (PBC) held its first pre-planned data review meeting and recommended the continuation of the Company’s Read the full article…

Genkyotex Logo

Genkyotex announces positive outcome of the Phase 2 trial of GKT831 in primary biliary cholangitis from the second independent SMB review

Posted Posted in Fund news, News, Portfolio News

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that the independent Safety Monitoring Board (SMB) for its Phase 2 trial of GKT831 for the treatment of Primary Biliary Cholangitis (PBC) held its second pre-planned data review meeting and recommended the continuation of the Company’s Read the full article…

Genkyotex Logo

Genticel and Genkyotex announce intention to enter into strategic combination

Posted Posted in Fund news, News, Portfolio News

Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a biotechnology company developinginnovative immunotherapies, and Genkyotex, a Swiss privately-held biopharmaceutical company and the leader in NOX therapies, announced today that Genticel has signed a contribution agreement with the shareholders of Genkyotex pursuant to which, subject to the approval of Genticel’s shareholders at a meeting expected to be held in Read the full article…

inositec Logo

Inositec AG Appoints Dr Frits van Alphen as Chief Medical Officer

Posted Posted in News, Portfolio News

Inositec, a pioneer in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), announced today the appointment of Frits van Alphen, MD, as Chief Medical Officer. Dr van Alphen has over 20 years of experience in clinical development and medical affairs, employed in roles of increasing responsibility. He has joined Inositec from Read the full article…

inositec Logo

Inositec AG secures CHF1.4m in seed financing to advance new class of inositol hexaphosphate-based drug candidates

Posted Posted in Fund news, News, Portfolio News

Inositec, a pioneer in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), announced today the closing of a CHF1.4 million (US$1.42 million) seed financing. Investors participating in the round included VI Partners via the Venture Incubator fund and Zürcher Kantonalbank. The proceeds will be used to progress a drug candidate from Read the full article…

inositec Logo

Inositec’s INS-3001 significantly reduces cardiovascular calcification in Proof of Concept study

Posted Posted in News, Portfolio News

Inositec, a pioneer in the development of life-saving small molecule drugs based on myo-inositol hexaphosphate (IP6), announced today that positive proof-of-concept data on INS-3001, a novel cardiovascular calcification inhibitor, were published in Nature Communications (DOI: 10.1038/s41467-019-14091-4). INS-3001 was found to be a potent and well tolerated inhibitor of pathological soft tissue calcification in preclinical studies. Calcification, particularly in arterial walls and cardiac valves, leads to an increase in cardiac events. Inositec is developing INS-3001 for a number of cardiovascular indications caused by calcification, including aortic valve stenosis.

Ledgy Logo

Inspired by Silicon Valley, Ledgy wants to help others give equity to employees

Posted Posted in News, Portfolio News

The fintech startup Ledgy and the law firms Kellerhals Carrard, Wenger & Vieli and LEXR partner up to help Swiss startups give out equity to their employees. According to a recent study by Index Ventures, European startup employees own half of the amount US employees own of their companies in terms of equity. This could be one of Read the full article…

iOnctura Logo

iOnctura extends Series A financing round to EUR 20.1m

Posted Posted in News, Portfolio News

iOnctura SA, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, today announces that it has raised an additional EUR 5.1 million bringing the total Series A financing to EUR 20.1 million. New investor 3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR joins the existing blue chip investor syndicate of M Ventures, INKEF Capital, VI Partners, and Schroder Adveq, which all participated in the extension.

iOnctura Logo

iOnctura raises EUR 15m in Series A financing

Posted Posted in Fund news, News, Portfolio News

Amsterdam, The Netherlands – January 23, 2020: iOnctura B.V., a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces today the closing of a EUR 15 million Series A financing. The financing was led by INKEF Capital and co-led by VI Partners with participation by new investors Schroder Read the full article…

Jenavalve Logo

JenaValve Technology appoints John T. Kilcoyne as Chief Executive Officer

Posted Posted in News, Portfolio News

JenaValve Technology, Inc., a developer, manufacturer and marketer of differentiated transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, today announced the appointment of veteran medical device executive John T. Kilcoyne as Chief Executive Officer, effective immediately. In addition, he will serve as a member of the Board of Directors. Kilcoyne Read the full article…

Jenavalve Logo

JenaValve Technology appoints Keith D. Dawkins, M.D., as Board Member

Posted Posted in News, Portfolio News

JenaValve Technology, Inc., a developer, manufacturer and marketer of differentiated transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, today announced the appointment of veteran medical device executive Keith D. Dawkins, M.D., as a new JenaValve board member. “As JenaValve advances its clinical development programs both in the US and Europe Read the full article…

Jenavalve Logo

JenaValve Technology closes US$50m equity financing led by Bain Capital

Posted Posted in News, Portfolio News

Irvine, California, USA – February 5, 2020: JenaValve Technology, Inc., developer and manufacturer of the JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital Life Sciences. Additional participants in the financing included existing investors Read the full article…

Jenavalve Logo

JenaValve Technology continues CE Mark study treating severe aortic stenosis with next-generation system

Posted Posted in News, Portfolio News

JenaValve Technology, Inc., a developer, manufacturer and marketer of differentiated transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, today announced successful patient enrollment in the CE Mark study of the next generation JenaValve Pericardial TAVR System utilizing the CoronatixTM Transfemoral Delivery Catheter for the percutaneous treatment of severe aortic stenosis. Read the full article…

Jenavalve Logo

JenaValve Technology implants initial patients in CE mark study for the treatment of severe aortic regurgitation with next-generation TAVR System

Posted Posted in News, Portfolio News

JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced initiation of patient enrollment and implantations associated with the CE Mark study of its next generation JenaValve Pericardial TAVR System using the Coronatix Transfemoral Delivery Catheter for the percutaneous treatment of patients with symptomatic, severe aortic regurgitation (AR). The JenaValve Pericardial TAVR Read the full article…

JenaValve Technology initiates U.S. patient enrollment in early feasibility study of next-generation TAVR system

Posted Posted in News, Portfolio News

JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced initiation of patient enrollment in the Early Feasibility Study (EFS) of its next generation JenaValve Pericardial TAVR System using the Everdur™ transcatheter heart valve (THV) and CoronatixTM Transfemoral Delivery Catheter at NewYork-Presbyterian/ Columbia University Medical Center (CUMC), New York City, and MedStar Washington Hospital Center, Read the full article…

Jenavalve Logo

JenaValve Technology initiates U.S. Patient enrollment in early feasibility study of next-generation TAVR system for the treatment of severe aortic stenosis and severe aortic regurgitation

Posted Posted in Fund news, News, Portfolio News

JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced initiation of patient enrollment in the Early Feasibility Study (EFS) of its next generation JenaValve Pericardial TAVR System using the Everdur™ transcatheter heart valve (THV) and CoronatixTM Transfemoral Delivery Catheter at NewYork-Presbyterian/ Columbia University Medical Center (CUMC), New York City, and MedStar Washington Hospital Center, Read the full article…

Jenavalve Logo

JenaValve Technology Receives FDA Approval for expanded IDE enrollment in the treatment of patients with severe aortic stenosis and severe aortic regurgitation

Posted Posted in News, Portfolio News

JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced U.S. Food and Drug Administration (FDA) approval of expansion of its Investigational Device Exemption (IDE) feasibility studies for the JenaValve Pericardial TAVR System with the Everdur™ transcatheter heart valve (THV) and CoronatixTM Transfemoral Delivery Catheter. The approval expands Read the full article…

Jenavalve Logo

JenaValve Technology strengthens senior leadership team in clinical affairs and operations

Posted Posted in News, Portfolio News

JenaValve Technology, Inc., a developer of a novel transcatheter aortic valve replacement (TAVR) system for the treatment of aortic valve disease, today announced the appointment of two veteran medical device executives Vinny Podichetty, MD, MS as Vice President, Clinical Affairs, and Jeff Thiel as Vice President, Operations, effective immediately.

Kuros Biosciences Logo

Kuros announces final result of capital increase – total gross proceeds of CHF 16.1m raised

Posted Posted in Fund news, News, Portfolio News

Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the final number of offered shares and gross proceeds from the rights offering and share placement, first announced on November 29, 2018, in which a total of 8,013,306 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00 Read the full article…

Kuros Biosciences Logo

Kuros Biosciences Announces Management Succession

Posted Posted in News, Portfolio News

Kuros Biosciences (SIX: KURN) announced today the appointment of Michael Grau as Chief Financial Officer (CFO) effective February 1, 2018. Michael Grau succeeds Harry Welten, who will step down as CFO on February 1, 2018 to focus on his boardroles and part-time CFO functions in privately held companies. Harry Welten will remain on the Board Read the full article…

Kuros Biosciences Logo

Kuros Biosciences enters convertible bond financing agreement for up to CHF 5m

Posted Posted in News, Portfolio News

Kuros Biosciences (SIX: KURN) today announced that it has entered into a convertible bond financing agreement with Nice & Green S.A. for up to a maximum of CHF 5 million. The facility is provided by Nice & Green, a private Swiss company which specializes in financing solutions tailored to the requirements of listed growth companies Read the full article…

Kuros Biosciences Logo

Kuros Biosciences obtains European patent covering osteoinductive materials

Posted Posted in News, Portfolio News

Kuros Biosciences AG (SIX: KURN) announced today that its Dutch subsidiary, Kuros Biosciences BV, has been granted the European patent, EP3021878, entitled “Method for producing an osteoinductive calcium phosphate and products thus obtained” bythe European Patent Office (EPO). The patent covers Kuros’ technology for osteoinductive calcium phosphates and their methods of production. The resulting unique Read the full article…

Kuros Biosciences Logo

Kuros Biosciences receives European clearance for MagnetOs Putty and prepares for commercial roll-out in the U.S. and Europe

Posted Posted in News, Portfolio News

Kuros Biosciences (SIX: KURN) announced today that it has received the CE Mark for MagnetOs Putty indicated for use as an osteoconductive and osteoinductive bonevoid filler in the skeletal system (i.e. spine, extremities, pelvis, cranium, mandible and maxilla). This market clearance allows commercialization of MagnetOs Putty in Europe, and complements the existing clearance for MagnetOs Read the full article…

Kuros Biosciences Logo

Kuros Biosciences receives US marketing clearance for intervertebral body fusion device

Posted Posted in News, Portfolio News

Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has received clearance for the Kuros TLIF cage from the U.S. Food and Drug Administration (FDA). The TLIF cage has been developed for the use with KUR-113, Kuros’s advanced Fibrin-PTH product candidate for spinal fusion. The combination of KUR-113 with the TLIF Read the full article…

Kuros Biosciences Logo

Kuros Biosciences reports first U.S. & UK sales of MagnetOs commercial roll-out in the U.S. and Europe on track

Posted Posted in News, Portfolio News

Kuros Biosciences (SIX: KURN) announced today it recorded the first commercial use last week of MagnetOs in the U.S., and the company expects to ramp up its commercial activities in Europe and the U.S. in the second half of 2018. Joshua M. Ammerman, M.D. of Washington Neurosurgical Associates in Washington DC, successfully performed minimally invasive Read the full article…

Kuros Biosciences Logo

Kuros Biosciences signs agreement on distribution of MagnetOs in Australia and New Zealand

Posted Posted in News, Portfolio News

Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a distribution agreement for the Australian and New Zealand healthcare markets with Surgical Specialties, a subsidiary of the Paragon Care Group (ASX: PGC), a leading provider of medical equipment, devices and consumables. Under the agreement, Kuros will supply Surgical Specialties Read the full article…

Kuros Biosciences Logo

Kuros Biosciences signs agreement to supply SeaSpine with bone graft incorporating Kuros’s advanced submicron surface technology

Posted Posted in News, Portfolio News

Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a private label Original Equipment Manufacturer (OEM) agreement with SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders.  Under the agreement Kuros will supply the bone graft in various Read the full article…

Kuros Biosciences to present promising clinical case studies with MagnetOs

Posted Posted in News, Portfolio News

Kuros Biosciences (SIX: KURN) will this week present results from several investigator-led clinical case studies of MagnetOs Granules at the 15th annual State of Spine Surgery Think Tank, a leading conference uniquely dedicated to innovation in spinal surgery. The case studies, in which MagnetOs Granules were implanted in the spine, were performed by Alwyn Jones MB ChB, BSc, MSc, Read the full article…

Kuros Biosciences Logo

Kuros receives FDA 510(k) clearance for extending commercial indications of MagnetOs Putty in the USA

Posted Posted in News, Portfolio News

Kuros Biosciences (SIX: KURN) today announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for extending MagnetOs Putty indications to use as a stand-alone bone graft in extremities and pelvis. This is in addition to the existing clearance for use of MagnetOs Granules and MagnetOs Putty as an autograft Read the full article…

Kuros Biosciences Logo

Kuros reports first patient treated in randomized controlled trial of MagnetOs in spinal fusion

Posted Posted in Fund news, News, Portfolio News

Kuros Biosciences (SIX: KURN) today announced that the first patient has been treated in an investigator-led multicenter randomized controlled study comparing MagnetOs with autologous bone in posterolateral spinal fusion. The University Medical Center Utrecht (UMCU) in the Netherlands is the principal investigating site for the study, which is entitled “A Randomized Controlled Trial of MagnetOs® Read the full article…

L.E.S.S. Logo

L.E.S.S. SA raises CHF 14m to accelerate the industrialization of their products in the automotive market.

Posted Posted in Fund news, News, Portfolio News

L.E.S.S. SA, a high tech company manufacturing a new generation of ultra-bright and ultra-thin lighting systems, announced today the closing of a CHF 14 million Series B financing round to accelerate the industrialization of their products in the automotive market. The round was led by new private and existing investors. L.E.S.S. SA was founded in Read the full article…

L.E.S.S. Logo

L.E.S.S. SA signs a multi-million contract with a renowned technology group

Posted Posted in News, Portfolio News

The year 2018 started very strong for L.E.S.S. SA, which owns a disruptive lighting technology based on nano-active optical fiber. The high-tech company closes a multi-million deal to supply its products in volume to a renown international technology group. This contract acknowledges the quality of L.E.S.S. innovation and crowns the long-term relationship between the two parties. Read the full article…

Gamaya Logo

Mahindra picks up 11.25% stake in Swiss agriculture technology firm Gamaya

Posted Posted in News, Portfolio News

Mahindra & Mahindra’s Farm Equipment Sector (FES) has acquired 11.25 per cent stake in Switzerland-based agriculture technology firm Gamaya for $4.3 million, the Indian company said in a statement on Friday. The investment will be done through a subscription to 300 Common Shares and 30,469 Series B Preferred Shares of Gamaya.  Gamaya, which works in Read the full article…

Medlumics Logo

MedLumics closes upsized EUR 18M financing round and appoints new Chairman

Posted Posted in Portfolio News

MedLumics, a privately held medical device company developing AblaView®, the first optically-guided real-time ablation catheter system for the treatment of Atrial Fibrillation (AF), announced today that it has closed an upsized EUR 18 million (USD 21.7 million) financing round and has appointed Rich Ferrari as Chairman of the Board of Directors. MedLumics’ optical catheter displays Read the full article…

Neocutis Logo

Merz Pharma takes over Swiss dermatology specialist Neocutis

Posted Posted in Fund news, News, Portfolio News

Merz Pharma Group (Frankfurt am Main) today announced that it has acquired the Swiss pharmaceutical company Neocutis S.A. The acquisition of the company`s cosmeceutical skin care business strengthens Merz`s market position in the field of aesthetic dermatology. “Neocutis is an innovative company with an excellent presence on the U.S. market, and a promising potential for development,” said Philip Burchard, CEO of Read the full article…

Myotest Logo

Myotest delivers next generation smart running features for smartphones & smartwatches

Posted Posted in News, Portfolio News

Myotest SA, leading licensor of biomechanics and smart coaching solutions, announced today the first software libraries designed for smartphones & smartwatches to help recreational runners to run better. These libraries collect and calculate key biomechanical running metrics in real-time and provide meaningful feedback to runners including ways to improve their running technique and to run Read the full article…

Nexthink Logo

Nexthink Achieves 74 Percent Growth in 2017; Increases Global Base of Customers, Partners and Staff

Posted Posted in News, Portfolio News

Nexthink®, a leader in digital experience management software for enterprises, today highlighted a successful 2017, announcing that it achieved a 74 percent increase in annual subscription revenue growth. This success was driven by a growing market for solutions that help enterprises to ensure a high-quality digital experience for their employees. Nexthink also announced it has Read the full article…

Nexthink Logo

Nexthink and Bracchin LLC Announce Partnership to Meet Increasing Demand

Posted Posted in News, Portfolio News

Nexthink®, a leader in digital employee experience management software for enterprises, and BRACHIN LLC, a leading IT enterprise software and consulting firm, announced a partnership to help satisfy a forecasted increase in demand for improved digital experience in the workplace. As employee digital experience becomes a top priority for CIOs, the demand for solutions and Read the full article…

Nexthink announces integration with Splunk

Posted Posted in News, Portfolio News

Nexthink®, a leader in digital employee experience management software for enterprises, today announced its new Splunk connector, an out-of-box integration with the leading provider of machine learning-based data analysis software. The Nexthink Splunk Connector addresses a typical complaint of Splunk users: a lack of specific end-point information in real-time related to security, operations and IT transformation projects. Read the full article…

Nexthink Logo

Nexthink raises $85m to help companies improve the digital employee experience

Posted Posted in Fund news, News, Portfolio News

Nexthink®, the leader in digital employee experience management software for enterprises, today announced it has secured an $85 million funding round. The financing was led by Index Ventures and includes participation from returning investors Highland Europe, Forestay Capital, VI Partners, Auriga Partners and Galéo Capital and new investors TOP Funds and Olivier Pomel, Co-founder and CEO of Datadog. Over the past few years, Nexthink has Read the full article…

Sonic Emotion Logo

Sennheiser Invests in Dear Reality & Sonic Emotion to Enhance Its VR/AR Capabilities

Posted Posted in Fund news, News, Portfolio News

Sennheiser is aiming to strengthen its position as a leading provider of immersive audio solutions with an investment in Dear Reality, experts in spatial audio algorithms and audio VR/AR software, and the acquisition of technologies from Sonic Emotion, a developer of 3D audio software and processing solutions. Both companies have developed unique expertise and tools for Read the full article…

Sequana Logo

Sequana Medical announces first patient enrolled in RED DESERT study for treatment of diuretic-resistant heart failure patients

Posted Posted in News, Portfolio News

Ghent, Belgium – January 7, 2020: Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that the first patient has been enrolled in the first-in-human repeated dose study of alfapump DSR (Direct Sodium Removal) for the treatment of diuretic-resistant heart Read the full article…

Sequana Logo

Sequana Medical announces presentation of positive DSR clinical proof-of-concept data demonstrating potential in volume overload due to heart failure

Posted Posted in News, Portfolio News

Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces the presentation of the positive results from the first-in-human single dose DSR proof-of-concept study for volume overload due Read the full article…

Sequana Logo

Sequana Medical announces unconditional FDA IDE approval to start alfapump® pivotal study (POSEIDON)

Posted Posted in News, Portfolio News

Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces that the U.S. Food and Drug Administration (FDA) has unconditionally approved its Investigational Device Exemption (IDE) application for Read the full article…

Sequana Logo

Sequana Medical establishes new corporate headquarters in Ghent, Belgium and raises €8.5m from Newton Biocapital, PMV and SFPI-FPIM and others

Posted Posted in Fund news, News, Portfolio News

Sequana Medical NV (“Sequana Medical” , the “Company” ), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today the opening of its new corporate headquarters in Ghent, Belgium, at the epicentre of the Flanders healthcare hub, and Read the full article…

Sequana Logo

Sequana Medical raises €27.5 million in IPO

Posted Posted in Fund news, News, Portfolio News

Sequana Medical NV – (“Sequana Medical”, the “Company”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces the results of its initial public offering of new shares, with the admission of all of Read the full article…

Sequana Logo

Sequana Medical receives breakthrough device designation from the FDA for its alfapump®

Posted Posted in News, Portfolio News

Sequana Medical NV (“Sequana Medical”, the “Company”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the alfapump® for the treatment Read the full article…

Sequana Logo

Sequana Medical reports positive data on use of the alfapump® in malignant ascites patients at the International Gynecologic Cancer Society

Posted Posted in Fund news, News, Portfolio News

Sequana Medical AG (“Sequana Medical”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today positive findings from its Retrospective Malignant Ascites Study. The study retrospectively evaluated 17 patients with malignant ascites that had been implanted with Read the full article…

Sequana Logo

Sequana Medical: strong interim results from RED DESERT alfapump® DSR study and business update

Posted Posted in News, Portfolio News

Ghent, Belgium – 22 October 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces positive interim results from the first five patients enrolled in the RED DESERT study, evaluating repeated dose treatment of alfapump DSR (Direct Sodium Removal) in diuretic-resistant heart failure patients. Sequana Medical also provides a business update.

Smart Valor Logo

Smart Valor startet Handelsplattform für Krypto-Assets

Posted Posted in News, Portfolio News

Zug, Switzerland – July 31, 2019: Das Jungunternehmen Smart Valor aus dem Crypto Valley hat die erste integrierte Handelsplattform für Krypto-Assets in der Schweiz gestartet. Es hat zum Ziel, die Börse zu einem international führenden Handelsplatz für digitale Wertpapiere auszubauen. Nach anderthalb Jahren Entwicklungszeit hat Smart Valor am Dienstag seine Handelsplattform für digitale Vermögenswerte gestartet. Zunächst können Read the full article…

Endosense Logo

St. Jude Medical Acquires Endosense

Posted Posted in Fund news, News, Portfolio News

St. Jude Medical, Inc. (NYSE: STJ), a global medical device company, today announced the acquisition of Endosense SA, a Switzerland-based company that has pioneered contact-force measurement in catheter ablation. The acquisition adds to the company’s leading electrophysiology portfolio and provides a robust platform for future product development. St. Jude Medical has made an initial payment of approximately 159 Read the full article…

SumUp and the Church of England bring cashless transactions to its congregations

Posted Posted in News, Portfolio News

The Church of England (www.churchofengland.org) is making contactless, virtual terminal, and SMS mobile payments available to over 16,000 churches, cathedrals, and religious sites throughout England, in a bid to make donations and transactions faster and easier for the Church’s congregations. The project is powered by Europe’s fastest growing company, SumUp (www.sumup.co.uk), whose payment solutions allow Read the full article…

Sumup Logo

SumUp receives a $371M loan to fuel its expansion

Posted Posted in News, Portfolio News

SumUp Inc., a six-year-old electronic payments startup, secured a 330 million-euro ($371 million) loan, backed by Bain Capital Credit, Goldman Sachs Private Capital and others. The London-based company plans to boost its customer base across 31 markets and develop its range of products, including via acquisitions. The startup makes credit-card readers to help businesses of Read the full article…

Myotest Logo

Suunto and Myotest announce technology collaboration

Posted Posted in Fund news, News, Portfolio News

Suunto, a global leader in sports precision instruments and Myotest, a global leader in advanced, accelerometer-based analysis and interpretation for digital sport, today announced technology collaboration for a new running solution. Suunto has a long heritage in building robust sports watches known for their precision and sports expertise targeted to performance oriented athletes, while Myotest’s personalized smart Read the full article…

Mila Logo

Swisscom übernimmt Mehrheit an Startup Mila

Posted Posted in Fund news, News, Portfolio News

Mit Swisscom Friends bietet Swisscom ihren Kunden gemeinsam mit dem Startup Mila seit zwei Jahren einen zusätzlichen, flexiblen und raschen Vor-Ort-Kundensupport. Swisscom hat nun die Mehrheit am Startup Mila übernommen. Mit der Investition baut der Schweizer ICT-Anbieter seine Aktivitäten im Bereich Shared Economy weiter aus. Mit Swisscom Friends erhalten Kunden auf einfache Weise kompetente und Read the full article…

Genkyotex Logo

The WHO recognizes NOX inhibitors as new therapeutic class and approves Setanaxib for GKT831

Posted Posted in Portfolio News

Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced that the World Health Organization (WHO) has recommended setanaxib as the international nonproprietary name (INN) for GKT831. The new stem “naxib” approved by WHO refers to NADPH oxidase inhibitors, and formally establishes a new therapeutic class under Read the full article…

Euippo Logo

Venture Incubator Invests in Equippo

Posted Posted in Fund news, News, Portfolio News

If you follow the Equippo blog, you’ll remember that Equippo announced its first financing round with b-to-v partners in June, 2015. Fast forward half a year, and we’re happy to announce the closing of our second major funding round with Swiss firm VI Partners. After celebrating Equippo’s first birthday on November 17th, this financing round comes at a Read the full article…

Xeltis Logo

Xeltis preclinical data extend potential of restorative approach to small diameter vessels

Posted Posted in News, Portfolio News

Positive preclinical results from the three different applications of Xeltis’ restorative small diameter blood vessels have been presented at 2019 International Symposium for Applied Cardiovascular Biology and Vascular Tissue Engineering in Zurich (CH). All studies showed encouraging patency of the devices, which have been used as carotid artery interposition grafts, arteriovenous shunts and coronary artery Read the full article…